Drug Profile
Research programme: migraine therapy - Orexo
Alternative Names: OX 40; OX641Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator PharmaKodex
- Developer Orexo
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Migraine
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 06 Mar 2012 Discontinued - Preclinical for Migraine in Sweden (PO)
- 21 Jul 2009 Preclinical development is ongoing in Sweden
- 21 Jul 2009 OX 641 is available for licensing worldwide (http://www.orexo.com)